Navigation Links
Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
Date:11/12/2007

w.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2006. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
3. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
4. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... and VANCOUVER , July 30, 2015 ... today that it will report its second quarter 2015 ... will host a conference call and live webcast at ... financial results, clinical development programs and a general corporate ... on to the Investor Relations page of the OncoGenex ...
(Date:7/30/2015)... FALLS, Ohio , July 30, 2015  Cleveland ... his OMTEC® 2015 keynote address last month that industry ... models in order to gain the efficiencies—and develop the ... Dr. Barsoum,s comments were preceded by ... avid entrepreneur and OMTEC moderator, who stressed that industry ...
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... today announced the national availability and receipt of ... pain medication monitoring program offering the industry,s highest ... and identify potential negative drug interactions before they ... concerns of prescription pain medication abuse by using ...
... ISIS ), the leader in antisense therapeutics, today ... Goldman Sachs 33rd Annual Global Healthcare Conference on Tuesday, June ... in Rancho Palos Verdes, CA. A live audio ... & Media" section of the Company,s Web site, www.isispharm.com ...
Cached Medicine Technology:PeaceHealth Laboratories' New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse 2
(Date:7/31/2015)... ... July 31, 2015 , ... Successful Import/Export Programs:, ... http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ports costs time, money and ... containment — or even destruction — of products, an FDA insider shows manufacturers ...
(Date:7/31/2015)... Tampa, FL (PRWEB) , ... July 31, 2015 ... ... cancer patients using the RenovoCath,™ a novel catheter that was developed for targeted ... locally-advanced pancreatic cancer are now being treated at Florida Hospital Tampa with the ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reputable source ... U.S. Women's National Soccer Team will face the Australia Women's National Team in two ... at Ford Field in Detroit and the second match will occur in Birmingham, Alabama ...
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased ... in Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based ... script display logic shows the script components to the agent only when wanted, and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, the innovative ... for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper is a ... understand the benefits of using medication management technologies . , ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3
... product line, sauces earning media attention, bi-coastal ... distribution underway, ... the launch of its new line of all-natural simmer sauces for,chicken. ... hit shelves at Whole Foods markets throughout the north Atlantic (MA,ME, ...
... Tubbs Jones released this statement commemorating the 19th,Anniversary of ... was World AIDS Day, a day where we pause,to ... that has proved to,be so devastating to so many ... 65 million people have been infected with,the HIV virus, ...
... Nventa,Biopharmaceuticals Corporation (TSX:NVN) announced today that Margot,Northey, Ph.D., ... of today to,pursue other interests., Jay M. ... commented,on the Board change: "As the former Dean ... knowledge, combined with her experience from,other Board positions, ...
... MISSISSAUGA, ON, Dec. 4 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals,Inc. ... the position taken by,the U.S. Food and Drug ... using the FDA,s Formal Dispute Resolution process. Cipher,received ... 2007 pertaining to its,New Drug Application (NDA) for ...
... Renovation of Local ... Pediatrician,s Office, HOUSTON, Dec. 4 ... Makeover" for pediatrician Dr.,Muhammad Shaikh at the Bissonet Medical Center in ... that AMERIGROUP Community,Care sponsored for the area,s physicians and its providers., ...
... 4 Aida,Pharmaceuticals (OTC Bulletin Board: AIDA) ... drug has been named as a "New ... Shanghai New High,Technology Service Centre ("SNHTSC"), a ... Municipal Government. This,designation will allow Rh-Apo2L to ...
Cached Medicine News:Health News:Good Clean Food's New Line of All-Natural Simmer Sauces for Chicken Hits Market Shelves 2Health News:Good Clean Food's New Line of All-Natural Simmer Sauces for Chicken Hits Market Shelves 3Health News:Tubbs Jones Commemorates World AIDS Day 2Health News:Cipher Appeals FDA's Decision On CIP-TRAMADOL ER 2Health News:AMERIGROUP Community Care Provides 'Doctor's Office Makeover' in Houston 2Health News:Rh-Apo2L Named as One of China's High-Tech Transforming Products by Chinese Government 2
Hartman Mosquito forceps, straight, 3.5"....
Curved 20 mm serrated jaws. Ring handle with ratchet lock and dull finish. Most popular size or model. Overall length 3.9 inches...
Shafts angled 45 degrees with 10 mm jaws. Serrated handle with polished finish. Crisscross serrated jaws. Most popular size or model....
Straight shafts with 16 mm long platform. Lengthwise serrated jaws with cross serrated tips. Serrated handle with polished finish. Platform: 2.4 mm wide....
Medicine Products: